HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage
- Landais, Elise;
- Murrell, Ben;
- Briney, Bryan;
- Murrell, Sasha;
- Rantalainen, Kimmo;
- Berndsen, Zachary T;
- Ramos, Alejandra;
- Wickramasinghe, Lalinda;
- Smith, Melissa Laird;
- Eren, Kemal;
- de Val, Natalia;
- Wu, Mengyu;
- Cappelletti, Audrey;
- Umotoy, Jeffrey;
- Lie, Yolanda;
- Wrin, Terri;
- Algate, Paul;
- Chan-Hui, Po-Ying;
- Karita, Etienne;
- Investigators, The IAVI Protocol C;
- Network, The IAVI African HIV Research;
- Ward, Andrew B;
- Wilson, Ian A;
- Burton, Dennis R;
- Smith, Davey;
- Pond, Sergei L Kosakovsky;
- Poignard, Pascal
- et al.
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736302/Abstract
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natural infection can help guide the rational design of an HIV vaccine. Here, we described a bnAb lineage targeting the Env V2 apex and the Ab-Env co-evolution that led to development of neutralization breadth. The lineage Abs bore an anionic heavy chain complementarity-determining region 3 (CDRH3) of 25 amino acids, among the shortest known for this class of Abs, and achieved breadth with only 10% nucleotide somatic hypermutation and no insertions or deletions. The data suggested a role for Env glycoform heterogeneity in the activation of the lineage germline B cell. Finally, we showed that localized diversity at key V2 epitope residues drove bnAb maturation toward breadth, mirroring the Env evolution pattern described for another donor who developed V2-apex targeting bnAbs. Overall, these findings suggest potential strategies for vaccine approaches based on germline-targeting and serial immunogen design.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.